ALLMedicine™ Growth Hormone Deficiency Center

Jan 19th, 2022 - Somatrogon (NGENLA®), a long-acting human growth hormone based on C-terminal peptide technology, is in development by Pfizer and OPKO Health for the treatment of growth hormone deficiency in pediatric and adult patients. Administered as a once-wee...

Jan 19th, 2022 - A 38 week dosing trial of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus placebo-control. A daily somatropin product arm is also included to assist clinical judgement on the trial results. Approximately 24...

Jan 19th, 2022 - Children often present to pediatricians and pediatric endocrinologists because of abnormal body growth, including both childhood growth failure and, less commonly, overgrowth. Sometimes the cause is evident, for example, growth hormone deficiency ...

Jan 15th, 2022 - We present the unique case of an adult Brazilian woman with severe short stature due to growth hormone deficiency with a heterozygous G to T substitution in the donor splice site of intron 3 of the growth hormone 1 (GH1) gene (c.291+1G>T). In this...

Jan 9th, 2022 - Standard-of-care treatment for growth hormone deficiency consists of daily subcutaneous injections of recombinant human growth hormone, also known as somatropin. Although somatropin treatment is well established, the burden of daily injections can...

Sep 17th, 2016 - Nonfunctioning pituitary adenomas (NFPAs) are among the most common pituitary lesions and may present with hypopituitarism and/or hyperprolactinemia. To review the existing literature as it pertains to preoperative endocrine assessment in the work...

Jan 19th, 2022 - A 38 week dosing trial of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus placebo-control. A daily somatropin product arm is also included to assist clinical judgement on the trial results. Approximately 24...

Jan 19th, 2022 - Children often present to pediatricians and pediatric endocrinologists because of abnormal body growth, including both childhood growth failure and, less commonly, overgrowth. Sometimes the cause is evident, for example, growth hormone deficiency ...

Sep 30th, 2021 - Background: Recombinant human growth hormone (GH) is used in the treatment of short stature due to growth hormone deficiency, Turner syndrome, Prader Willi syndrome, small for gestational age with failure of catch up growth, chronic renal failure ...

Aug 26th, 2021 - The TRIIM-X trial is an expanded pilot clinical study that will evaluate a personalized combination treatment regimen for thymus regeneration. The thymus is a part of the immune system that declines markedly with age, and regenerating it may preve...

Jul 29th, 2021 - GHD is the most common anterior pituitary abnormality after traumatic brain injury (TBI). It can occur as a result of either direct pituitary or indirect hypothalamic injury. Sports-related repetitive head trauma might induce pituitary dysfunction...

Jan 24th, 2022 - Note that some links may require registration or subscription. Strained hospitals are calling potentially infectious healthcare workers back to their posts, citing the CDC's latest guidance. (Washington Post) NIAID Director Anthony Fauci, MD, said...

Sep 2nd, 2021 - The US Food and Drug Administration (FDA) has approved lonapegsomatropin (Skytrofa, Ascendis Pharma), the first weekly subcutaneous injectable growth hormone for children with growth hormone deficiency (GHD). The approval was based on the findings...

Mar 12th, 2021 - Children who have been treated for brain tumors often experience significant weight gain, and new findings suggest that this could be a sign of hypothalamic-pituitary (HP) dysfunction. "We believe that endocrine surveillance should be initiated ea...

Dec 21st, 2020 - Children who received recombinant human growth hormones (rhGHs) were at an increased risk of cardiovascular events once they reached early adulthood in a Swedish cohort study. Among 3,408 patients on rhGHs in childhood, the hazard ratios for any c...

Nov 2nd, 2020 - Endocrine diseases of any type — not just diabetes — can represent a cardiovascular risk and patients with those disorders should be screened for high cholesterol, according to a new clinical practice guideline from the Endocrine Society. "The sim...